These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation. Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245 [TBL] [Abstract][Full Text] [Related]
6. Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells. Flis S; Bratek E; Chojnacki T; Piskorek M; Skorski T Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31614827 [TBL] [Abstract][Full Text] [Related]
10. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1. Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934 [TBL] [Abstract][Full Text] [Related]
11. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609 [TBL] [Abstract][Full Text] [Related]
12. High Massimino M; Stella S; Tirrò E; Pennisi MS; Stagno F; Vitale SR; Romano C; Tomarchio C; Parrinello NL; Manzella L; Di Raimondo F; Vigneri P Onco Targets Ther; 2023; 16():803-816. PubMed ID: 37807980 [TBL] [Abstract][Full Text] [Related]
13. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108 [TBL] [Abstract][Full Text] [Related]
14. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601 [No Abstract] [Full Text] [Related]
15. The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells. Mourgues L; Imbert V; Nebout M; Colosetti P; Neffati Z; Lagadec P; Verhoeyen E; Peng C; Duprez E; Legros L; Rochet N; Maguer-Satta V; Nicolini FE; Mary D; Peyron JF Leukemia; 2015 Oct; 29(10):1993-2002. PubMed ID: 25925206 [TBL] [Abstract][Full Text] [Related]
16. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro. Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634 [TBL] [Abstract][Full Text] [Related]
17. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012 [TBL] [Abstract][Full Text] [Related]
18. Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. Kamachi K; Ureshino H; Watanabe T; Yoshida N; Yamamoto Y; Kurahashi Y; Fukuda-Kurahashi Y; Hayashi Y; Hirai H; Yamashita S; Ushijima T; Okada S; Kimura S Cancer Lett; 2022 Feb; 526():273-283. PubMed ID: 34875342 [TBL] [Abstract][Full Text] [Related]
19. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Trinh A; Khamari R; Fovez Q; Mahon FX; Turcq B; Bouscary D; Maboudou P; Joncquel M; Coiteux V; Germain N; Laine W; Dekiouk S; Jean-Pierre S; Maguer-Satta V; Ghesquiere B; Idziorek T; Quesnel B; Kluza J; Marchetti P Mol Metab; 2022 Jan; 55():101410. PubMed ID: 34863941 [TBL] [Abstract][Full Text] [Related]
20. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]